Merck & Company (MRK)

$111.01 +2.75 (2.54%)
Market Cap 268.70B
Revenue (ttm) 64.17B
Net Income (ttm) 17.12B
EPS (ttm) N/A
PE Ratio 12.62
Forward PE 13.75
Profit Margin 26.68%
Debt to Equity Ratio 0.77
Volume 11,964,600
Avg Vol 14,395,558
Day's Range N/A - N/A
Shares Out 2.48B
Stochastic %K 78%
Beta 0.29
Analysts Strong Sell
Price Target $113.58

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
AStrokeOfLuck
AStrokeOfLuck Jan. 15 at 4:49 PM
$NVO $LLY $MRK $PFE $BMY
0 · Reply
jogabonito84
jogabonito84 Jan. 15 at 4:37 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:42 PM
$MRK ripped 32% in three months — and it still isn’t enough. Bear case stays intact. ⚠️ The rally hasn’t fixed the fundamentals: declining estimates, Keytruda’s upcoming LOE, and Gardasil declines are why the stock remains sell-rated. See why this bounce doesn’t change the thesis 👉 https://www.zacks.com/stock/news/2817821/why-mercks-32-rally-isnt-enough-to-change-the-bearish-view?cid=sm-stocktwits-2-2817821-teaser-29039&ADID=SYND_STOCKTWITS_TWEET_2_2817821_TEASER_29039
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 2:42 PM
$MRK up 32.3% in 3 months — Is the rally sustainable? 🚀 Keytruda's driving sales growth, but with looming patent expiration in 2028 and declining Gardasil sales due to weak performance in China, challenges persist. Plus, it's a Zacks Rank #5 (Strong Sell) with declining earnings estimates due to M&A costs. See the full analysis here 👉 https://www.zacks.com/stock/news/2817821/why-mercks-32-rally-isnt-enough-to-change-the-bearish-view?cid=sm-stocktwits-2-2817821-body-29037&ADID=SYND_STOCKTWITS_TWEET_2_2817821_BODY_29037
0 · Reply
MQuick
MQuick Jan. 15 at 1:30 PM
$GANX $SNY $RHHBY $MRK wake up!
0 · Reply
cielo1
cielo1 Jan. 15 at 7:58 AM
$IFRX https://www.amgenoncology.com/targets/C5.html Let's see it amgen! $AMGN $MRK $RHHBY Genentech So many uses, who is going to bring Gohibic and Izicopan to patients world wide? 🌎
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 1:34 AM
$SLS Another Phase 3 Failure in the Advanced Ovarian Cancer Space "the median OS was 14.2 months (95% CI, 13.0-16.1) vs 13.0 months (95% CI, 11.9-15.1) in each respective arm" https://www.cancernetwork.com/view/atezolizumab-combo-does-not-significantly-boost-survival-in-ovarian-cancer - $IMGN 's Elahere achieved a 16.46 Month MOS and was bought by $ABBV for 10.1B. - GPS + Keytruda $MRK achieved a Phase 2 MOS of 18.4 Months in this same Setting. Now that the AML P3 is completely deRisked and everyone knows GPS is getting FDA Approval for AML Remission Maintenance - MRK - May be willing to Pay the $40B SLS' CEO wants - they already Know GPs +Keytruda will Open 20+ WT1+ Cancer Settings.
0 · Reply
Buy_SoFi
Buy_SoFi Jan. 14 at 10:04 PM
$TLTFF Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/166009-ferring-pharmaceuticals-and-theralase-r-technologies-announce-clinical-development-agreement-to-investigate-combination-therapy-in-bladder-cancer.html $CGON $IBRX $MRK $JNJ
0 · Reply
free2dream
free2dream Jan. 14 at 8:37 PM
$MRNA $MRK should buy Moderna while it is still sub $20B . Idiotic not to, all the Moderna oncology trials have extremely good results . $XBI $SRPT
0 · Reply
jogabonito84
jogabonito84 Jan. 14 at 8:00 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
1 · Reply
Latest News on MRK
Is Merck Stock A Trap At $110?

Jan 15, 2026, 9:10 AM EST - 3 hours ago

Is Merck Stock A Trap At $110?

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 10:25 PM EST - 2 days ago

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

Jan 12, 2026, 8:01 PM EST - 2 days ago

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 4 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD JNJ KO NKE PG

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

Jan 10, 2026, 9:52 AM EST - 5 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON JNJ KO

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

Jan 9, 2026, 2:58 PM EST - 5 days ago

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

RVMD

Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck

Jan 9, 2026, 1:25 PM EST - 5 days ago

Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck

FDX SLB

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 5 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN BMY LLY NVO PFE

Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list

Jan 8, 2026, 5:53 PM EST - 6 days ago

Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list

Merck in talks to buy biotech Revolution Medicines, FT reports

Jan 8, 2026, 3:56 PM EST - 6 days ago

Merck in talks to buy biotech Revolution Medicines, FT reports

RVMD

Cramer's Stop Trading: Merck

Jan 8, 2026, 10:31 AM EST - 7 days ago

Cramer's Stop Trading: Merck

Merck: Fundamentals Amplified By A Momentum Breakout

Jan 8, 2026, 8:00 AM EST - 7 days ago

Merck: Fundamentals Amplified By A Momentum Breakout

The Big 3: XRT, MRK, CAT

Jan 7, 2026, 1:00 PM EST - 7 days ago

The Big 3: XRT, MRK, CAT

XRT CAT

Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation

Jan 7, 2026, 12:36 PM EST - 8 days ago

Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

Jan 7, 2026, 8:01 AM EST - 8 days ago

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

Quant Q&A With Steven Cress

Jan 7, 2026, 7:00 AM EST - 8 days ago

Quant Q&A With Steven Cress

CLS CRDO ET FIX PFE

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Jan 7, 2026, 6:50 AM EST - 8 days ago

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Merck to Complete Acquisition of Cidara Therapeutics

Jan 7, 2026, 6:45 AM EST - 8 days ago

Merck to Complete Acquisition of Cidara Therapeutics

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Jan 7, 2026, 6:30 AM EST - 8 days ago

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 6:45 AM EST - 10 days ago

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Top 10 High-Yield Dividend Stocks For January 2026

Jan 3, 2026, 1:20 AM EST - 12 days ago

Top 10 High-Yield Dividend Stocks For January 2026

ADP CMCSA CNS EOG KDP MKC NEE

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

Jan 2, 2026, 5:06 PM EST - 12 days ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD JNJ KO NKE PG

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Jan 1, 2026, 3:11 AM EST - 14 days ago

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck: Framework For Success

Jan 1, 2026, 2:57 AM EST - 14 days ago

Merck: Framework For Success

Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis

Dec 30, 2025, 12:03 PM EST - 16 days ago

Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 26 days ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK AMGN GILD NVS SNY

US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy

Dec 19, 2025, 4:03 PM EST - 26 days ago

US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 26 days ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD GSK NVS SNY

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Dec 19, 2025, 2:39 PM EST - 26 days ago

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 26 days ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD GSK NVS SNY

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 27 days ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY NVO

Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case

Dec 18, 2025, 10:47 PM EST - 27 days ago

Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case

Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report

Dec 18, 2025, 11:55 AM EST - 4 weeks ago

Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report

Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers

Dec 17, 2025, 3:37 PM EST - 4 weeks ago

Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers

Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial

Dec 17, 2025, 12:45 PM EST - 4 weeks ago

Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Dec 17, 2025, 10:14 AM EST - 4 weeks ago

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

PFE

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Dec 17, 2025, 6:45 AM EST - 4 weeks ago

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Dec 12, 2025, 8:45 AM EST - 4 weeks ago

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm

Dec 9, 2025, 11:51 AM EST - 5 weeks ago

FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm

BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research

Dec 9, 2025, 8:00 AM EST - 5 weeks ago

BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

Dec 9, 2025, 7:18 AM EST - 5 weeks ago

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)

Dec 6, 2025, 8:00 AM EST - 5 weeks ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)

ADP AEG APH ARCC ARE ATO CAG

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Dec 5, 2025, 1:35 PM EST - 5 weeks ago

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

GSK SNY

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Dec 4, 2025, 1:53 PM EST - 5 weeks ago

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

PLRX

FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

Dec 4, 2025, 12:05 PM EST - 6 weeks ago

FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 6:03 PM EST - 6 weeks ago

Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 4:13 AM EST - 6 weeks ago

Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript

17 dividend-stock bargains from a value manager with a stellar track record

Dec 2, 2025, 12:11 PM EST - 6 weeks ago

17 dividend-stock bargains from a value manager with a stellar track record

BMY CIVI CMCSA CVS MOS MTH OMC

Top 10 High-Yield Dividend Stocks For December 2025

Dec 1, 2025, 2:20 PM EST - 6 weeks ago

Top 10 High-Yield Dividend Stocks For December 2025

ACN ADP CMCSA EOG NEE NKE PAG

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

Dec 1, 2025, 6:45 AM EST - 6 weeks ago

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

AStrokeOfLuck
AStrokeOfLuck Jan. 15 at 4:49 PM
$NVO $LLY $MRK $PFE $BMY
0 · Reply
jogabonito84
jogabonito84 Jan. 15 at 4:37 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:42 PM
$MRK ripped 32% in three months — and it still isn’t enough. Bear case stays intact. ⚠️ The rally hasn’t fixed the fundamentals: declining estimates, Keytruda’s upcoming LOE, and Gardasil declines are why the stock remains sell-rated. See why this bounce doesn’t change the thesis 👉 https://www.zacks.com/stock/news/2817821/why-mercks-32-rally-isnt-enough-to-change-the-bearish-view?cid=sm-stocktwits-2-2817821-teaser-29039&ADID=SYND_STOCKTWITS_TWEET_2_2817821_TEASER_29039
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 2:42 PM
$MRK up 32.3% in 3 months — Is the rally sustainable? 🚀 Keytruda's driving sales growth, but with looming patent expiration in 2028 and declining Gardasil sales due to weak performance in China, challenges persist. Plus, it's a Zacks Rank #5 (Strong Sell) with declining earnings estimates due to M&A costs. See the full analysis here 👉 https://www.zacks.com/stock/news/2817821/why-mercks-32-rally-isnt-enough-to-change-the-bearish-view?cid=sm-stocktwits-2-2817821-body-29037&ADID=SYND_STOCKTWITS_TWEET_2_2817821_BODY_29037
0 · Reply
MQuick
MQuick Jan. 15 at 1:30 PM
$GANX $SNY $RHHBY $MRK wake up!
0 · Reply
cielo1
cielo1 Jan. 15 at 7:58 AM
$IFRX https://www.amgenoncology.com/targets/C5.html Let's see it amgen! $AMGN $MRK $RHHBY Genentech So many uses, who is going to bring Gohibic and Izicopan to patients world wide? 🌎
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 1:34 AM
$SLS Another Phase 3 Failure in the Advanced Ovarian Cancer Space "the median OS was 14.2 months (95% CI, 13.0-16.1) vs 13.0 months (95% CI, 11.9-15.1) in each respective arm" https://www.cancernetwork.com/view/atezolizumab-combo-does-not-significantly-boost-survival-in-ovarian-cancer - $IMGN 's Elahere achieved a 16.46 Month MOS and was bought by $ABBV for 10.1B. - GPS + Keytruda $MRK achieved a Phase 2 MOS of 18.4 Months in this same Setting. Now that the AML P3 is completely deRisked and everyone knows GPS is getting FDA Approval for AML Remission Maintenance - MRK - May be willing to Pay the $40B SLS' CEO wants - they already Know GPs +Keytruda will Open 20+ WT1+ Cancer Settings.
0 · Reply
Buy_SoFi
Buy_SoFi Jan. 14 at 10:04 PM
$TLTFF Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/166009-ferring-pharmaceuticals-and-theralase-r-technologies-announce-clinical-development-agreement-to-investigate-combination-therapy-in-bladder-cancer.html $CGON $IBRX $MRK $JNJ
0 · Reply
free2dream
free2dream Jan. 14 at 8:37 PM
$MRNA $MRK should buy Moderna while it is still sub $20B . Idiotic not to, all the Moderna oncology trials have extremely good results . $XBI $SRPT
0 · Reply
jogabonito84
jogabonito84 Jan. 14 at 8:00 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
1 · Reply
GoodNewsBull
GoodNewsBull Jan. 14 at 6:14 PM
Id worry less about the "Dems" & more about your trades. Even Hunter knew $MRK was going higher & he was on Crack! $DJT
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 14 at 5:58 PM
$MRK Share Price: $109.61 Contract Selected: Feb 06, 2026 $110 Calls Buy Zone: $2.68 – $3.31 Target Zone: $5.08 – $6.20 Potential Upside: 79% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TheVulcanDevilWhale
TheVulcanDevilWhale Jan. 14 at 5:21 PM
$MRK
0 · Reply
ZacksResearch
ZacksResearch Jan. 14 at 3:37 PM
Is $MRK riding too hard on Keytruda? ⚠️ Q4 could be the real test. Keytruda drives over half of pharma revenues, but softer Q3 sales have investors zeroed in on whether the blockbuster can still lift Q4 top-line performance. Find out what this means for Merck’s Q4 earnings setup 👉 https://www.zacks.com/stock/news/2817216/will-keytruda-continue-to-aid-mercks-top-line-in-q4-earnings?cid=sm-stocktwits-2-2817216-teaser-28825&ADID=SYND_STOCKTWITS_TWEET_2_2817216_TEASER_28825
0 · Reply
serenityNOW
serenityNOW Jan. 14 at 3:23 PM
$IBRX $MRK $3.5 and $4 strike calls have some considerable OI for this week opex (max pain is on $1.5)... i say if $4 is reached there's maybe a possibility of a gamma squeeze but that's a BIG "IF" considering the history of price action w this ticker and seemingly incorrigible tendency to dilute as soon as there's any progress in SP....
0 · Reply
Oshin11
Oshin11 Jan. 14 at 3:16 PM
$IBRX The question is if they are going to dilute now after this news or if the Saudis will make any cash contribution with this deal or perhaps buying a batch (1000 doses)of Anktiva. If the stock goes up to $4 a bunch of warrants will kick in as well and it would bring anither $100 million or so in. But most importantly this approval was the nail in the coffin to make this company cash flow positive this year. Sell $MRK buy $IBRX
0 · Reply
Bullishbruk
Bullishbruk Jan. 14 at 3:01 PM
$IBRX We suspected $MRK was shorting $IBRX — now with fresh positive NSCLC data (Jan 13, 2026) showing ANKTIVA + checkpoints like Keytruda delivers statistically significant immune restoration (sustained ALC increase in first-line; 77% restoration in later-line across 151 patients) tied to better survival — we may see mass short covering. This “Immunotherapy 2.0” combo rescues exhausted checkpoints in a huge market, with ongoing Phase 3 (ResQ201A) adding fuel. Short interest 120M shares (35% of float, with some chatter of higher effective levels and squeeze potential on X today). More catalyst on its way! Squeeze incoming? #ANKTIVA #NSCLC #Immunotherapy
0 · Reply
jogabonito84
jogabonito84 Jan. 14 at 2:49 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
0 · Reply
Fingerlickengood
Fingerlickengood Jan. 14 at 2:41 PM
$CDXS $MRK "Dr. Moore holds a bachelor’s degree in Pharmacology with Honors and a PhD in Cell Biology from Manchester University, England." https://ir.codexis.com/company-information/management-team
0 · Reply
Fingerlickengood
Fingerlickengood Jan. 14 at 2:39 PM
$CDXS $MRK www.bioxconomy.com/modalities/enzymes-open-door-simpler-efficient-oligo-synthesis
0 · Reply
ZacksResearch
ZacksResearch Jan. 14 at 2:37 PM
$MRK's 32.8% rally in 6 months compared to the industry’s 23.2% rise — is the momentum sustainable? 🚀 🔬 Keytruda drives growth but Q3 sales were weaker than expected 🦠 Strong prospects with new SC formulation & potential expansion into new indications 📉 Yet, MRK holds a Zacks Rank #5 (Strong Sell) Discover the full analysis here 👉 https://www.zacks.com/stock/news/2817216/will-keytruda-continue-to-aid-mercks-top-line-in-q4-earnings?cid=sm-stocktwits-2-2817216-body-28824&ADID=SYND_STOCKTWITS_TWEET_2_2817216_BODY_28824
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 12:15 PM
Enter: $MRK Calls Strike Price: $109 Expiry Date: FEB 06 2026 Buy in Price: $3.20 - $3.77 Sell Price: $7.24 Profit : +92% (Turn every $1 into $1.92) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply